Cellectar Biosciences, Inc. Resources
Patients
News & Media
Investors
Contact
Cellectar Biosciences, Inc.
Home
About
Overview
Partnerships
Management Team
Board of Directors
Platform
Overview
Posters & Publications
Product Pipeline
Overview
Iopofosine
Clinical Studies
Overview
Waldenstrom’s Macroglobulinemia Pivotal Study
Recruiting
Relapsed or Refractory Select B-Cell Malignancies Clinical Study
Recruiting
Children With Relapsed or Refractory Malignant Cancer Clinical Study
Active, not recruiting
Patients
News & Media
Investors
Contact
Contact
Clinical Studies
Clinical Studies
Overview
Waldenstrom’s Macroglobulinemia Pivotal Study
Relapsed or Refractory Select B-Cell Malignancies Clinical Study
Children With Relapsed or Refractory Malignant Cancer Clinical Study
Contact us for more information on the iopofosine Clinical Studies
Name
Email
I am a:
Patient
Friend, Family, Caregiver
Physician/Healthcare Provider
Clinical Trial
Select Your Trial
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia
Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma
Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia
Message
This site is protected by hCaptcha and its
Privacy Policy
and
Terms of Service
apply.
Submit